AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 61439 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa treatment
Number of subjects: 242
Study 30919233 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-trough-based TDM
Number of subjects: 65
Study 30919233 — intervention group
Group type: COMPARATOR
Intervention: Trough-only-based TDM
Number of subjects: 65
Study 28969327 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB (infusion of rocuronium 2 mg ml -1)
Number of subjects: 128
Study 28969327 — intervention group
Group type: COMPARATOR
Intervention: Standard NMB (bolus of rocuronium 10 mg or increased depth of anaesthesia)
Number of subjects: 128
Study 28969327 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 128
Study 28969327 — intervention group
Group type: COMPARATOR
Intervention: Deep NMB and Standard NMB
Number of subjects: 128
Study 26255515 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy (stimulated on specific points once a week for 4 weeks)
Number of subjects: 90
Study 26255515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program of auricular point sticking therapy and TCM psychotherapy (4 weeks treatment)
Number of subjects: 90
Study 26255515 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (oral administration of deanxit, one tablet a day for 4 weeks)
Number of subjects: 90
Study 23153291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with wavelength 830 nm, dose of 2 J/cm² and additional spots of 1 J/cm².
Number of subjects: 60
Study 23153291 — intervention group
Group type: COMPARATOR
Intervention: Placebo light treatment (control group).
Number of subjects: 60
Study 22303699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride sustained release tablets administered at 12h, 24h, 48h postoperation and before cleaning up procession
Number of subjects: 188
Study 22303699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no administration of Tramadol)
Number of subjects: 188
Study 19509011 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 months vigorous aerobic exercise, supervised 3 times per week)
Number of subjects: 36
Study 19509011 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic group (no aerobic exercise)
Number of subjects: 36
Study 16684263 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus triple therapy for H. pylori
Number of subjects: 650
Study 16684263 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron alone
Number of subjects: 650
Study 16684263 — intervention group
Group type: COMPARATOR
Intervention: Continuously infected children (control group)
Number of subjects: 650
Study 15225901 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (ME) intensity (0.55-0.65 x maximal aerobic power)
Number of subjects: 23
Study 15225901 — intervention group
Group type: COMPARATOR
Intervention: Low exercise (LE) intensity (0.30-0.40 x maximal aerobic power)
Number of subjects: 23
Study 16054522 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with dipeptide alanyl‐glutamine
Number of subjects: 40
Study 16054522 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (standard)
Number of subjects: 40
Study 10336000 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively charged filters applied after 3 days of storage
Number of subjects: 0
Study 10336000 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma radiation
Number of subjects: 0
Study 10336000 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively charged filters
Number of subjects: 0
Study 10336000 — intervention group
Group type: COMPARATOR
Intervention: Untreated apheresis PCs
Number of subjects: 0
Study 10336000 — intervention group
Group type: COMPARATOR
Intervention: Buffy coat PCs
Number of subjects: 0
Study 7554318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen (1.25 mg daily)
Number of subjects: 15
Study 7554318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐oestradiol (100 micrograms daily)
Number of subjects: 15
Study 7554318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oestrogen treatments
Number of subjects: 15
Study 7554318 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither oral nor transdermal oestrogen
Number of subjects: 15
Study 2298404 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) treatment arm (60 mg/m2 starting dose, maximum cumulative dose of 500 mg/m2)
Number of subjects: 181
Study 2298404 — intervention group
Group type: COMPARATOR
Intervention: No Doxorubicin (no-DOX arm)
Number of subjects: 181
Study 7436691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 0
Study 7436691 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 7436691 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan (L‐tryptophan)
Number of subjects: 0
Study 31851171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nooclerin (deanol aceglumate)
Number of subjects: 60
Study 31851171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26811172 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 94
Study 26791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 1131
Study 26791477 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 1131
Study 24862342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 62
Study 24862342 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 62
Study 22072307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination docetaxel and carboplatin (cDC): weekly docetaxel 30 mg/m² on days 1 and 8 and carboplatin AUC = 6 on day 1, every 3 weeks
Number of subjects: 150
Study 22072307 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy with docetaxel then carboplatin (sDC): docetaxel 30 mg/m² on days 1 and 8 for 6 cycles followed by carboplatin AUC = 6 on day 1 for 6 cycles
Number of subjects: 150
Study 20541024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids plus a second immunosuppressive agent
Number of subjects: 180
Study 17255748 — intervention group
Group type: EXPERIMENTAL
Intervention: Remune, an inactivated HIV‐1 vaccine
Number of subjects: 0
Study 15821223 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - continuous infusion starting with 50 mg/kg/4 h followed by 100 mg/kg/24 h for 44 h (n = 18)
Number of subjects: 35
Study 15821223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 35
Study 11975151 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural priming task focusing on similarities
Number of subjects: 0
Study 11975151 — intervention group
Group type: COMPARATOR
Intervention: Procedural priming task focusing on differences
Number of subjects: 0
Study 9813512 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. clonidine 1 microgram kg‐1
Number of subjects: 100
Study 9813512 — intervention group
Group type: COMPARATOR
Intervention: saline bolus
Number of subjects: 100
Study 8762660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobesilate of calcium with dexamethasone acetate and lidocaine (Treatment A)
Number of subjects: 40
Study 8762660 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone capronate with dibucaine hydrochloride (Treatment B)
Number of subjects: 40
Study 2496791 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily for six weeks
Number of subjects: 161
Study 2496791 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily for six weeks
Number of subjects: 161
Study 31285554 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/B ratio (n=63)
Number of subjects: 126
Study 31285554 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/B ratio with high HOMA-IR and low fiber intake (n=17)
Number of subjects: 126
Study 31285554 — intervention group
Group type: COMPARATOR
Intervention: Low P/B ratio (n=63)
Number of subjects: 126
Study 31501120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Aids (HAs)
Number of subjects: 4
Study 31501120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implants (CIs)
Number of subjects: 4
Study 31501120 — intervention group
Group type: COMPARATOR
Intervention: Qualitative research (q-COACH)
Number of subjects: 4
Study 28613971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Self-Help Booklet (CBT-SHB) with usual care
Number of subjects: 332
Study 28613971 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care alone
Number of subjects: 332
Study 25727273 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-turn protocol
Number of subjects: 13
Study 25727273 — intervention group
Group type: COMPARATOR
Intervention: Automated-turn protocol
Number of subjects: 13
Study 24399261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (HRA augmented with health promotion and education activities)
Number of subjects: 180
Study 24399261 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (HRA only)
Number of subjects: 180
Study 24399261 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 180
Study 23034084 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea interventions (DIA)
Number of subjects: 800
Study 23034084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue interventions (DEN)
Number of subjects: 800
Study 23034084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diarrhea and dengue interventions (DIADEN)
Number of subjects: 800
Study 23034084 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 800
Study 19714630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone (> or =10 mg/m(2)/week, maximum dosage 1 mg/kg/week)
Number of subjects: 594
Study 19714630 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept alone (0.8 mg/kg/week, maximum dose 50 mg)
Number of subjects: 594
Study 19714630 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus Methotrexate (MTX)
Number of subjects: 594
Study 19714630 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups (MTX, etanercept, etanercept plus MTX)
Number of subjects: 594
Study 17533209 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Number of subjects: 60
Study 17533209 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts
Number of subjects: 60
Study 17533209 — intervention group
Group type: COMPARATOR
Intervention: TLC diet alone
Number of subjects: 60
Study 15232517 — intervention group
Group type: EXPERIMENTAL
Intervention: IT 2.5 mg levobupivacaine + 25 microg fentanyl (LF)
Number of subjects: 40
Study 15232517 — intervention group
Group type: COMPARATOR
Intervention: IT 2.5 mg levobupivacaine (L)
Number of subjects: 40
Study 11146073 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg misoprostol
Number of subjects: 185
Study 11146073 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol
Number of subjects: 185
Study 10079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (specific antibiotics not detailed)
Number of subjects: 387
Study 10079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (immunocorrection)
Number of subjects: 387
Study 10079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Various physiochemical methods in complex treatment
Number of subjects: 387
Study 7974832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin provision in newborns from healthy mothers
Number of subjects: 0
Study 7974832 — intervention group
Group type: COMPARATOR
Intervention: Vitamin provision in newborns from mothers with hypertensive disease
Number of subjects: 0
Study 2610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release Capsule (Elantan), 50 mg
Number of subjects: 18
Study 2610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release Tablet, 50 mg
Number of subjects: 18
Study 2610720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release Capsule, 100 mg
Number of subjects: 18
Study 2610720 — intervention group
Group type: COMPARATOR
Intervention: Non Sustained Release Tablets, 40 mg
Number of subjects: 18
Study 2610720 — intervention group
Group type: COMPARATOR
Intervention: Non Sustained Release Tablets, 2 x 20 mg
Number of subjects: 18
Study 56903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch
Number of subjects: 0
Study 56903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 60
Number of subjects: 0
Study 56903 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte group
Number of subjects: 0
Study 31445343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482
Study 31445343 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus adjunctive personalized therapy
Number of subjects: 482
Study 29088099 — intervention group
Group type: EXPERIMENTAL
Intervention: Anserine/carnosine supplementation (ACS) 1.0 g (3:1) for 3 months
Number of subjects: 60
Study 29088099 — intervention group
Group type: EXPERIMENTAL
Intervention: Anserine/carnosine supplementation (ACS)
Number of subjects: 60
Study 25744209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-session prevention program
Number of subjects: 236
Study 23890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Large patent foramen ovale (PFO)
Number of subjects: 80
Study 23890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or large PFO
Number of subjects: 80
Study 23890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial septal aneurysms
Number of subjects: 80
Study 23890906 — intervention group
Group type: COMPARATOR
Intervention: PFO size and headache days
Number of subjects: 80
Study 22185740 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 31
Study 22185740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18585750 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-interval forced choice (2-IFC) procedure
Number of subjects: 0
Study 18585750 — intervention group
Group type: COMPARATOR
Intervention: Two successive Yes-No signal detection tasks
Number of subjects: 0
Study 16145319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (0.05 mg 17[beta]-estradiol every 24 hours combined with 5 mg oral dydrogesterone daily)
Number of subjects: 90
Study 16145319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (2 mg 17[beta]-estradiol semihydrate every 24 hours combined with 10 mg dydrogesterone)
Number of subjects: 90
Study 16145319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy
Number of subjects: 90
Study 16145319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone therapy
Number of subjects: 90
Study 16145319 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (both routes)
Number of subjects: 90
Study 12165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast irradiation of 42.5 Gy in 16 fractions over 22 days (short arm)
Number of subjects: 1234
Study 12165639 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation of 50 Gy in 25 fractions over 35 days (long arm)
Number of subjects: 1234
Study 12165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm (22-day schedule)
Number of subjects: 1234
Study 12165639 — intervention group
Group type: COMPARATOR
Intervention: Long arm (35-day schedule)
Number of subjects: 1234
Study 10089978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell activity measured by tryptase levels in effusion
Number of subjects: 33
Study 10089978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptase levels in effusion of atopic patients
Number of subjects: 33
Study 10089978 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mast cells in middle ear biopsies
Number of subjects: 33
Study 10089978 — intervention group
Group type: COMPARATOR
Intervention: Presence of mast cells in normal ears
Number of subjects: 33
Study 7844665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib oligosaccharide conjugate (HbOC) at birth
Number of subjects: 150
Study 7844665 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoids (DT) at birth
Number of subjects: 150
Study 7844665 — intervention group
Group type: COMPARATOR
Intervention: Control group (HbOC or PRP-tetanus toxoid conjugate (PRP-T) starting at 2 months)
Number of subjects: 150
Study 2185461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker bottom crutches
Number of subjects: 150
Study 2185461 — intervention group
Group type: COMPARATOR
Intervention: Conventional axillary crutches
Number of subjects: 150
Study 681999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units)
Number of subjects: 110
Study 681999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 110
Study 681999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 110
Study 28631179 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib alone
Number of subjects: 501
Study 28631179 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib in combination with cytarabine
Number of subjects: 501
Study 28631179 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine alone
Number of subjects: 501
Study 28631179 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine in combination with volasertib
Number of subjects: 501
Study 27632147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders
Number of subjects: 830
Study 27632147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders for newly initiated ART patients (<3 months)
Number of subjects: 830
Study 27632147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mobile phone text reminders for urban newly initiated ART patients
Number of subjects: 830
Study 27632147 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 830
Study 25035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine 110 mg/m² once every 6 weeks
Number of subjects: 153
Study 25035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg once every 2 weeks
Number of subjects: 153
Study 25035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks and lomustine 90 mg/m² every 6 weeks
Number of subjects: 153
Study 25035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks and lomustine 110 mg/m² every 6 weeks
Number of subjects: 153
Study 25035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bevacizumab and lomustine groups
Number of subjects: 153
Study 25035291 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 153
Study 25035291 — intervention group
Group type: COMPARATOR
Intervention: Lomustine alone
Number of subjects: 153
Study 25035291 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab and lomustine 90 mg/m²
Number of subjects: 153
Study 22327087 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-week half marathon training program (TP)
Number of subjects: 20
Study 22327087 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study 19927018 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 16
Study 19927018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 18752692 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based intervention consisting of six food items with modified cation content and 500 ml of maas (fermented milk)/d for 8 weeks
Number of subjects: 80
Study 18752692 — intervention group
Group type: COMPARATOR
Intervention: Control diet providing the same quantities of targeted foods but of standard commercial composition and 500 ml/d of artificially sweetened cooldrink
Number of subjects: 80
Study 18752692 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based intervention
Number of subjects: 80
Study 16248242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulating control (ASC)
Number of subjects: 65
Study 16248242 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (Control)
Number of subjects: 65
Study 12969415 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency management condition (usual condition + emergency-management-focused teaching)
Number of subjects: 219
Study 12969415 — intervention group
Group type: COMPARATOR
Intervention: Usual condition (reading and discussion program)
Number of subjects: 219
Study 11137328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol (1 mg) combined with Chlormadinone Acetate 5 mg
Number of subjects: 99
Study 11137328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 50 microg/24 h with Norethisterone Acetate (11.2 or 22.4 mg)
Number of subjects: 99
Study 11137328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9186533 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional induction treatment with daunorubicin and cytarabine
Number of subjects: 118
Study 9186533 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 118
Study 9186533 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 118
Study 9186533 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 118
Study 9186533 — intervention group
Group type: COMPARATOR
Intervention: Patients below 40 years of age
Number of subjects: 118
Study 9186533 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic vs Autologous bone marrow transplantation
Number of subjects: 118
Study 8244812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20 Gy in a single fraction using 9-20 MeV electrons)
Number of subjects: 26
Study 8244812 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy (daily 150-180 cGy fractions to 45-55 Gy in 5-6 weeks)
Number of subjects: 26
Study 8244812 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 26
Study 8244812 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative radiotherapy or external beam radiotherapy
Number of subjects: 26